Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Raises $10M, En Route to Launching Targeted Sequencing Test for Cancer Dx

Premium

Foundation Medicine has raised $10 million of a planned $20.5 million financing round, according to documents filed with the US Securities and Exchange Commission this week.

The equity comes from a single, unnamed backer, and adds to the $25 million it raised in a Series A financing round last year.

The company, which is aiming for CLIA-certification by the end of the year, is currently developing a targeted sequencing-based cancer test that it plans to launch in the second quarter of 2012 (CSN 6/8/2011). It is also collaborating with pharmaceutical companies Novartis and Celgene (CSN 4/13/2011 and 5/17/2011).

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.